BRPI0707488B8 - método para a produção de uma composição de epoprostenol, composição farmacêutica e solução estável - Google Patents

método para a produção de uma composição de epoprostenol, composição farmacêutica e solução estável

Info

Publication number
BRPI0707488B8
BRPI0707488B8 BRPI0707488A BRPI0707488A BRPI0707488B8 BR PI0707488 B8 BRPI0707488 B8 BR PI0707488B8 BR PI0707488 A BRPI0707488 A BR PI0707488A BR PI0707488 A BRPI0707488 A BR PI0707488A BR PI0707488 B8 BRPI0707488 B8 BR PI0707488B8
Authority
BR
Brazil
Prior art keywords
composition
epoprostenol
producing
solution
pharmaceutical composition
Prior art date
Application number
BRPI0707488A
Other languages
English (en)
Inventor
R Palepu Naglesh
Original Assignee
Actelion One Sa
Actelion Pharmaceuticals Ltd
Generamedix Inc
Scidose Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38345694&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0707488(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion One Sa, Actelion Pharmaceuticals Ltd, Generamedix Inc, Scidose Llc filed Critical Actelion One Sa
Publication of BRPI0707488A2 publication Critical patent/BRPI0707488A2/pt
Publication of BRPI0707488B1 publication Critical patent/BRPI0707488B1/pt
Publication of BRPI0707488B8 publication Critical patent/BRPI0707488B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

método para a produção de uma composição de epoprostenol, composição farmacêutica e solução estável. a invenção refere-se a uma composição de epoprostenol estável que pode ser combinada com fluidos iv comercialmente disponíveis e pode ser administrada em sua forma reconstituída e/ou diluída sob condições ambientais de cerca de 15-30ºc por mais do que 24 horas. a composição de preferência contém (a) epoprostenol ou um sal do mesmo; (b) um agente de alcalinização; e (c) uma base, de modo que quando reconstituída ou em solução, a solução tem um ph (maior que) 11. são também descritos métodos para a produção da composição liofilizada.
BRPI0707488A 2006-02-03 2007-02-02 método para a produção de uma composição de epoprostenol, composição farmacêutica e solução estável BRPI0707488B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US76476906P 2006-02-03 2006-02-03
US60/764,769 2006-02-03
US77256306P 2006-02-13 2006-02-13
US60/772,563 2006-02-13
US78342906P 2006-03-20 2006-03-20
US60/783,429 2006-03-20
PCT/US2007/002948 WO2007092343A2 (en) 2006-02-03 2007-02-02 Novel epoprostenol formulation and method of making thereof

Publications (3)

Publication Number Publication Date
BRPI0707488A2 BRPI0707488A2 (pt) 2011-05-03
BRPI0707488B1 BRPI0707488B1 (pt) 2020-05-26
BRPI0707488B8 true BRPI0707488B8 (pt) 2021-05-25

Family

ID=38345694

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0707488A BRPI0707488B8 (pt) 2006-02-03 2007-02-02 método para a produção de uma composição de epoprostenol, composição farmacêutica e solução estável

Country Status (14)

Country Link
US (2) US8318802B2 (pt)
EP (1) EP1993557B1 (pt)
JP (1) JP5415771B2 (pt)
KR (1) KR101351668B1 (pt)
CN (1) CN101410119B (pt)
BR (1) BRPI0707488B8 (pt)
CA (2) CA2868998A1 (pt)
DK (1) DK1993557T3 (pt)
ES (1) ES2558705T3 (pt)
HU (1) HUE026166T2 (pt)
PL (1) PL1993557T3 (pt)
PT (1) PT1993557E (pt)
SI (1) SI1993557T1 (pt)
WO (1) WO2007092343A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2868998A1 (en) 2006-02-03 2007-08-16 Actelion Pharmaceuticals Ltd. Novel epoprostenol formulation and method of making thereof
CN101827612A (zh) 2007-09-07 2010-09-08 联合治疗公司 针对革兰氏阴性细菌具有选择性杀菌活性的缓冲液及其使用方法
BR112012002578B8 (pt) * 2009-08-07 2021-05-25 Scipharm Sarl usos de treprostinil ou de um derivado ou de um sal farmaceuticamente aceitável do mesmo para tratamento da fibrose cística
CN101669904B (zh) * 2009-09-29 2011-06-22 北京中海康医药科技发展有限公司 一种依前列醇脂质纳米粒及制备方法
US20120321728A1 (en) * 2011-06-15 2012-12-20 Ven Subbiah Nutritional formula for managing angina pectoris
JP5917034B2 (ja) * 2011-07-15 2016-05-11 ニプロ株式会社 カルシウムブロッカーを含有する固形医薬組成物
CN103585119A (zh) * 2013-11-13 2014-02-19 北京泰德制药股份有限公司 一种包含依前列醇及其药用盐的稳定化制剂及其制备方法
ITMI20142149A1 (it) * 2014-12-16 2016-06-16 L I A Di Giuseppe Capasso Apparato di diagnosi differenziale in medicina adattato per determinare la sequenza di test ottimale atta ad identificare una patologia secondo criteri di appropriatezza diagnostica
HU231031B1 (hu) * 2016-03-23 2019-12-30 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Megnövelt stabilitású epoprostenol nátrium és eljárás előállítására
US10912778B2 (en) 2016-12-14 2021-02-09 Respira Therapeutics, Inc. Methods for treatment of pulmonary hypertension
CN109330982A (zh) * 2018-09-13 2019-02-15 常州市第四制药厂有限公司 依前列醇冻干粉及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2021581B (en) 1978-05-17 1982-10-20 Wellcome Found Stabilisation of pgl derivatives
ZA787353B (en) * 1978-05-17 1980-08-27 Wellcome Found Pharmaceutical formulations
US7230014B1 (en) 1997-10-14 2007-06-12 Eisai Co., Ltd. Pharmaceutical formulation comprising glycine as a stabilizer
US6803386B2 (en) * 2002-01-16 2004-10-12 United Therapeutics Corporation Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
DE10225551A1 (de) * 2002-06-06 2003-12-24 Schering Ag Verwendung von oral verfügbaren Prostacyclinderivaten für die Herstellung eines Arzneimittels zur Behandlung von Krankheiten, die mit Knochenmarködemen assoziiert sind
JP2007526329A (ja) 2004-03-04 2007-09-13 ワイス 賦形剤の結晶化を改善するための凍結乾燥法
CA2868998A1 (en) 2006-02-03 2007-08-16 Actelion Pharmaceuticals Ltd. Novel epoprostenol formulation and method of making thereof

Also Published As

Publication number Publication date
HUE026166T2 (en) 2016-05-30
CA2641393C (en) 2014-12-16
US8598227B2 (en) 2013-12-03
BRPI0707488B1 (pt) 2020-05-26
EP1993557A4 (en) 2012-07-25
US8318802B2 (en) 2012-11-27
KR101351668B1 (ko) 2014-01-14
ES2558705T3 (es) 2016-02-08
DK1993557T3 (en) 2015-12-07
BRPI0707488A2 (pt) 2011-05-03
WO2007092343A3 (en) 2008-01-17
CN101410119B (zh) 2012-03-07
JP2009525344A (ja) 2009-07-09
PT1993557E (pt) 2016-02-10
EP1993557A2 (en) 2008-11-26
CA2868998A1 (en) 2007-08-16
US20090088468A1 (en) 2009-04-02
CA2641393A1 (en) 2007-08-16
CN101410119A (zh) 2009-04-15
WO2007092343A2 (en) 2007-08-16
PL1993557T3 (pl) 2016-05-31
KR20090004867A (ko) 2009-01-12
US20130018093A1 (en) 2013-01-17
JP5415771B2 (ja) 2014-02-12
SI1993557T1 (sl) 2016-01-29
EP1993557B1 (en) 2015-11-11

Similar Documents

Publication Publication Date Title
BRPI0707488B8 (pt) método para a produção de uma composição de epoprostenol, composição farmacêutica e solução estável
BRPI0615819B8 (pt) processo para preparar uma composição de distribuição de fármaco compreendendo um agente ativo e uma micropartícula fumaril dicetopiperazina cristalina.
EA200801460A1 (ru) Рекомбинантные моновалентные антитела и способы их получения
NO20091509L (no) Substituerte tetrahydropyrrolopyrazinforbindelser med affinitet KCNQ2/3 K+ kanal og anvendelse derav i medikamenter
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
MA32771B1 (fr) Mutants fgf21 et leurs utilisations
BR112014033102A2 (pt) produto para uso no tratamento profilático ou terapêutico de uma emoção negativa ou comportamento introvertido
MX2010004389A (es) Formulaciones de vancomicina liposomales.
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
WO2007143607A3 (en) Method of treating atrophic vaginitis
AU2007247480A8 (en) Pharmaceutical combination comprising 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and an NSAID
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
BRPI0508063A (pt) processo para a manufatura de uma composição farmacêutica, nsaid, e, composição farmacêutica
BRPI0512699A (pt) compostos, processo para a fabricação de compostos, composições farmacêuticas, método para tratamento terapêutico e/ou profilático de doenças que são moduladas por agonistas lxr alfa e/ou lxr beta e uso de tais compostos
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
BRPI0720230B8 (pt) formulação nutricional oralmente administrável, uso da formulação, e, composição
BRPI0611526A2 (pt) composição tópica contendo gelatina
BR112015002004A2 (pt) isolamento de mutantes melhoradores de tráfego de proteínas transportadoras de medicamentos
BRPI0518891A2 (pt) composiÇço farmacÊutica àptica tàpica
BR112014027213A2 (pt) nova composição de alfentanil para o tratamento da dor aguda
DE602006015968D1 (de) Zubereitungen von pro-insulin-c-peptid mit verzögerter freisetzung
EA200501301A1 (ru) Ментоловые растворы лекарственных препаратов
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: GENERAMEDIX, INC. (US)

Free format text: TRANSFERIDO DE: SCIDOSE, LLC

B25A Requested transfer of rights approved

Owner name: ACTELION ONE SA (LU)

Free format text: TRANSFERIDO DE: GENERAMEDIX, INC.

B25G Requested change of headquarter approved

Owner name: ACTELION ONE SA (LU)

B25A Requested transfer of rights approved

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/05/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/02/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF